Head-To-Head Analysis: OS Therapies (OSTX) vs. Its Peers

OS Therapies (NYSE:OSTX) is one of 450 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare OS Therapies to related companies based on the strength of its valuation, profitability, analyst recommendations, earnings, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares OS Therapies and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OS Therapies	N/A	-$7.79 million	-1.91
OS Therapies Competitors	$443.86 million	-$69.05 million	-7.47

OS Therapies’ peers have higher revenue, but lower earnings than OS Therapies. OS Therapies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for OS Therapies and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OS Therapies	0	0	3	2	3.40
OS Therapies Competitors	4776	9992	16016	364	2.38

OS Therapies presently has a consensus price target of $18.00, suggesting a potential upside of 997.56%. As a group, “Pharmaceutical preparations” companies have a potential upside of 106.75%. Given OS Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than its peers.

Profitability

This table compares OS Therapies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OS Therapies	N/A	N/A	-569.57%
OS Therapies Competitors	-2,615.58%	-412.72%	-44.45%

Institutional and Insider Ownership

39.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.8% of OS Therapies shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

OS Therapies beats its peers on 8 of the 12 factors compared.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.